The Centre for III-nitride technology (C3NiT), of which Epiluvac is a key member, has been successfully exploiting cutting-edge research for next generation, power, and high frequency electronics for the last 5 years. In recognition of this success, Vinnova, the Swedish Innovation Agency, has agreed to support C3NiT with funding for an additional 5 years. Epiluvac will remain an important part of this ongoing endeavor.